Cost-Effectiveness of Treating Upper Limb Spasticity Due to Stroke with Botulinum Toxin Type A: Results from the Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial

Stroke imposes significant burdens on health services and society, and as such there is a growing need to assess the cost-effectiveness of stroke treatment to ensure maximum benefit is derived from limited resources. This study compared the cost-effectiveness of treating post-stroke upper limb spasticity with botulinum toxin type A plus an upper limb therapy programme against the therapy programme alone. Data on resource use and health outcomes were prospectively collected for 333 patients with post-stroke upper limb spasticity taking part in a randomized trial and combined to estimate the incremental cost per quality adjusted life year (QALY) gained of botulinum toxin type A plus therapy relative to therapy alone. The base case incremental cost-effectiveness ratio (ICER) of botulinum toxin type A plus therapy was £93,500 per QALY gained. The probability of botulinum toxin type A plus therapy being cost-effective at the England and Wales cost-effectiveness threshold value of £20,000 per QALY was 0.36. The point estimates of the ICER remained above £20,000 per QALY for a range of sensitivity analyses, and the probability of botulinum toxin type A plus therapy being cost-effective at the threshold value did not exceed 0.39, regardless of the assumptions made.

[1]  R. Brooks.  EuroQol: the current state of play. , 1996, Health policy.

[2]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[3]  S. Hesse,et al.  Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial , 1998, Clinical rehabilitation.

[4]  David E. Booth,et al.  Analysis of Incomplete Multivariate Data , 2000, Technometrics.

[5]  B. Bhakta,et al.  Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial , 2000, Journal of neurology, neurosurgery, and psychiatry.

[6]  E. Elovic,et al.  Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. , 2002, The New England journal of medicine.

[7]  B J O'Brien,et al.  Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods , 2002, Statistical methods in medical research.

[8]  Anthony J Culyer,et al.  National Institute for Clinical Excellence and its value judgments , 2004, BMJ : British Medical Journal.

[9]  Andrea Manca,et al.  Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. , 2004, Health economics.

[10]  Jeroen N. Struijs,et al.  International Comparison of Stroke Cost Studies , 2004, Stroke.

[11]  S. Gillard,et al.  Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. , 2005, Journal of rehabilitation medicine.

[12]  A. McCormick,et al.  i Botulinum Toxin A for Upper and Lower Limb Spasticity : A Systematic Review Technology Report , 2005 .

[13]  J. Dolly,et al.  The structure and mode of action of different botulinum toxins , 2006, European journal of neurology.

[14]  L. Curtis,et al.  Unit Costs of Health and Social Care 2016 , 2015 .

[15]  L. Turner-Stokes,et al.  Spasticity in adults: management using botulinum toxin: National Guidelines. , 2018 .

[16]  C. Wolfe,et al.  Cost of stroke in the United Kingdom. , 2008, Age and ageing.

[17]  H. Rodgers,et al.  Botulinum Toxin for the Upper Limb After Stroke (BoTULS) Trial: Effect on Impairment, Activity Limitation, and Pain , 2011, Stroke.

[18]  L. Kalra,et al.  The Economic Burden of Stroke in the United Kingdom , 2012, PharmacoEconomics.